Shares of GoPro, Inc. (GPRO) are trading up on the day and are moving higher despite estimate cuts below Street by analysts at Citigroup (C). The banking giant keeps $90 price target.
On valuation measures, GoPro Inc. stock it’s trading at a forward P/E multiple of 17.49x, and at a multiple of 32.72x this year’s estimated earnings. The t-12-month revenue at GoPro Inc. is $1.70 billion. GPRO ‘s ROE for the same period is 41.58%.
Shares of the $4.86 billion market cap company are down 45.22% year-over-year and 43.48% year-to-date.
GoPro Inc., currently with a median Wall Street price target of $71.00 and a high target of $105.00, rose $0.84 to $36.56 in recent trading.
Oracle Corporation (ORCL) was reiterated a ‘Buy’ by Stifel analysts on Thursday. The broker however, cut its price target on the stock to $45 from $47.
Shares have traded today between $36.50 and $37.67 with the price of the stock fluctuating between $35.14 to $46.71 over the last 52 weeks.
Oracle Corp. shares are currently changing hands at 16.78x this year’s forecasted earnings, compared to the industry’s 2.01x earnings multiple. Ticker has a t-12 price/sales ratio of 4.34. EPS for the same period registers at $2.21.
Shares of Oracle have lost $1.20 to $37.07 in midday trading on Thursday, giving it a market cap of roughly $161 billion. The stock traded as high as $46.71 in Dec. 24, 2014.
FedEx Corporation (FDX) was reiterated as ‘Buy’ with a $175 from $195 price target on Thursday by UBS.
FedEx Corp. recently traded at $150.13, a gain of $0.50 over Wednesday’s closing price. The name has a current market capitalization of $42.41 billion.
As for passive income investors, the company pays shareholders $1.00 per share annually in dividends, yielding 0.66%.
Shares of Yahoo! Inc. (YHOO) are down $0.45 to $30.95 in mid-day trading after FBR Capital lowered its target price on the name by 11 points to $39 a share to reflect the change in the value of Alibaba (BABA) and its impact on sum-of-the-parts valuation.
YHOO shares recently lost $0.37 to $31.03. In the past 52 weeks, shares of Sunnyvale, California-based company have traded between a low of $29.00 and a high of $52.62.
Shares are down 37.83% since the beginning of year.
Mirati Therapeutics, Inc. (MRTX) had its rating lowered from ‘Overweight’ to ‘Neutral’ by analysts at Piper Jaffray on Thursday. The firm sees shares as fairly valued at $45 from $50, versus $44.34 close. Currently there are 4 analysts that rate MRTX a ‘Buy’ versus zero rating it a ‘Sell’ or a ‘Hold’.
MRTX was down $2.53 at $41.81 in mid-day trade, moving within a 52-week range of $13.69 to $52.00. The name, valued at $686.30 million, opened at $42.93.